Trial Profile
A Randomized Trial of Rituximab vs Alemtuzumab vs Alemtuzumab + Rituximab as Consolidation Therapy for Patients With Chronic Lymphocytic Leukemia (CLL) With Evidence of Residual Disease Following Prior Chemo(Immuno)Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2013
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 28 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jan 2010 Status changed from recruiting to active, no longer recruiting according to M.D. Anderson Cancer Center record
- 15 Oct 2008 Integrated ClinicalTrials.gov record NCT00771602.